MCID: OVR010
MIFTS: 47

Ovarian Brenner Tumor

Categories: Cancer diseases, Endocrine diseases, Reproductive diseases

Aliases & Classifications for Ovarian Brenner Tumor

MalaCards integrated aliases for Ovarian Brenner Tumor:

Name: Ovarian Brenner Tumor 12 15
Brenner Tumor 44 73
Benign Ovarian Brenner Tumor 12
Benign Brenner Tumor 73

Classifications:



External Ids:

Disease Ontology 12 DOID:2636
MeSH 44 D001948
NCIt 50 C3872 C39954
SNOMED-CT 68 74739000

Summaries for Ovarian Brenner Tumor

Disease Ontology : 12 An ovarian benign neoplasm that has material basis in the surface epithelium of the ovary.

MalaCards based summary : Ovarian Brenner Tumor, also known as brenner tumor, is related to cystadenoma and transitional cell carcinoma. An important gene associated with Ovarian Brenner Tumor is UPK3A (Uroplakin 3A), and among its related pathways/superpathways are Cytoskeletal Signaling and Keratinization. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include ovary, testis and kidney, and related phenotypes are embryo and renal/urinary system

Related Diseases for Ovarian Brenner Tumor

Diseases in the Ovarian Brenner Tumor family:

Malignant Ovarian Brenner Tumor

Diseases related to Ovarian Brenner Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 204)
# Related Disease Score Top Affiliating Genes
1 cystadenoma 30.7 KRT20 KRT7 MME
2 transitional cell carcinoma 30.4 KRT18 KRT20 KRT7 UPK3A
3 ovarian mucinous neoplasm 30.2 KRT20 KRT7 WT1
4 papilloma 30.2 KRT13 KRT20 KRT7
5 ovarian lymphoma 30.1 KRT18 MME
6 ovarian cancer 1 30.1 KRT7 PAX8 WT1
7 diffuse peritoneal leiomyomatosis 30.0 CALB2 KIT WT1
8 bladder urothelial carcinoma 30.0 GATA3 KRT20 KRT7 UPK3A
9 endometrial cancer 29.9 KIT KRT7 MME MUC16 PAX8
10 clear cell adenocarcinoma 29.7 KRT20 KRT7 MUC16 PAX2 PAX8
11 malignant ovarian brenner tumor 12.5
12 brenner tumor of the vagina 12.3
13 testicular brenner tumor 12.2
14 brenner tumor of ovary 11.6
15 papillary serous adenocarcinoma 10.4 KRT20 KRT7
16 bladder adenocarcinoma 10.3 KRT20 KRT7
17 meibomian cyst 10.3 KRT20 KRT7
18 renal pelvis transitional cell carcinoma 10.3 KRT7 UPK3A
19 struma ovarii 10.3
20 cystic basal cell carcinoma 10.3 KRT20 KRT7
21 seminal vesicle adenocarcinoma 10.3 KRT20 KRT7
22 transverse colon cancer 10.3 KRT20 KRT7
23 appendix adenocarcinoma 10.3 KRT20 KRT7
24 malignant syringoma 10.3 KRT20 KRT7
25 papillary transitional carcinoma 10.3 KRT20 KRT7
26 benign mesothelioma 10.3 KRT7 WT1
27 eyelid carcinoma 10.3 KRT20 KRT7
28 krukenberg carcinoma 10.3 KRT20 KRT7
29 large intestine adenocarcinoma 10.3 KRT20 KRT7
30 linitis plastica 10.3 KRT20 KRT7
31 malignant epithelial mesothelioma 10.3 THBD WT1
32 lung acinar adenocarcinoma 10.3 KRT20 KRT7
33 inverted transitional papilloma 10.3 GATA3 KRT7
34 small cell carcinoma of the bladder 10.3 KRT20 KRT7
35 adenomyoma 10.3 KRT7 MME
36 head injury 10.3 PRL THBD
37 glandular cystitis 10.3 KRT20 KRT7 UPK3A
38 renal adenoma 10.3 KRT7 WT1
39 vulval paget's disease 10.3 KRT20 KRT7 UPK3A
40 adenocarcinoma 10.3
41 vulva adenocarcinoma 10.3 KRT20 KRT7 UPK3A
42 proliferating trichilemmal cyst 10.3 KRT18 KRT7
43 renal pelvis adenocarcinoma 10.3 KRT7 PAX8
44 adenoid squamous cell carcinoma 10.3 KRT20 KRT7
45 vulvar disease 10.3 KRT13 KRT7 UPK3A
46 sensory organ benign neoplasm 10.3 KRT7 PAX8
47 transitional papilloma 10.2 KRT13 KRT18
48 mucinous cystadenocarcinoma 10.2 KRT20 KRT7 MUC16
49 vulva cancer 10.2 KRT13 KRT7 UPK3A
50 endosalpingiosis 10.2 KRT7 PAX8 WT1

Graphical network of the top 20 diseases related to Ovarian Brenner Tumor:



Diseases related to Ovarian Brenner Tumor

Symptoms & Phenotypes for Ovarian Brenner Tumor

MGI Mouse Phenotypes related to Ovarian Brenner Tumor:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 embryo MP:0005380 9.56 GATA3 KIT KRT18 PAX2 PAX8 SALL4
2 renal/urinary system MP:0005367 9.32 ANO1 GATA3 KIT KRT7 PAX2 PAX8

Drugs & Therapeutics for Ovarian Brenner Tumor

Drugs for Ovarian Brenner Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 93)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
2
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
3
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
4
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
5
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
6
Gemcitabine Approved Phase 3,Phase 2 95058-81-4 60750
7
Cyclophosphamide Approved, Investigational Phase 3 6055-19-2, 50-18-0 2907
8
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
9
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 1 56-86-0 33032
10 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
11 Antimitotic Agents Phase 3,Phase 2,Phase 1
12 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
13 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
14 Immunoglobulin G Phase 3,Phase 2,Phase 1
15 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
16 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
17 Antibodies Phase 3,Phase 2,Phase 1
18 Immunoglobulins Phase 3,Phase 2,Phase 1
19 Immunologic Factors Phase 3,Phase 2,Phase 1
20 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
21 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
22 Mitogens Phase 3,Phase 2,Phase 1
23 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
24 Antineoplastic Agents, Alkylating Phase 3,Phase 1
25 Alkylating Agents Phase 3,Phase 1
26 Carotenoids Phase 3
27 Micronutrients Phase 3
28 Trace Elements Phase 3
29 Antimetabolites, Antineoplastic Phase 3,Phase 2
30 Antiviral Agents Phase 3,Phase 2
31 Antimetabolites Phase 3,Phase 2
32 Anti-Infective Agents Phase 3,Phase 2
33 taxane Phase 3
34 Peripheral Nervous System Agents Phase 3,Not Applicable
35 Antirheumatic Agents Phase 3
36 Analgesics Phase 3
37
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
38
Belinostat Approved, Investigational Phase 2 866323-14-0
39
Iodine Approved, Investigational Phase 1, Phase 2 7553-56-2 807
40
Metformin Approved Phase 2 657-24-9 14219 4091
41
Xylometazoline Approved, Investigational Phase 2 526-36-3 5709
42
Doxil Approved June 1999 Phase 2,Phase 1 31703
43 Antibiotics, Antitubercular Phase 2,Phase 1
44 Anti-Bacterial Agents Phase 2,Phase 1
45 Histone Deacetylase Inhibitors Phase 2
46 Protein Kinase Inhibitors Phase 2,Phase 1
47
Erlotinib Hydrochloride Phase 2,Phase 1 183319-69-9 176871
48 Imatinib Mesylate Phase 2 220127-57-1 123596
49 Hypoglycemic Agents Phase 2
50
Bortezomib Approved, Investigational Phase 1 179324-69-7 387447 93860

Interventional clinical trials:

(show top 50) (show all 54)
# Name Status NCT ID Phase Drugs
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
2 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
3 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
4 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
5 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
6 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3 carboplatin;paclitaxel
7 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
8 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
9 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
10 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
11 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
12 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
13 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
14 VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01666444 Phase 2 pegylated liposomal doxorubicin (PLD);VTX-2337;Placebo
15 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
16 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
17 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2 belinostat;carboplatin
18 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
19 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
20 Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Completed NCT00217529 Phase 1, Phase 2 carboplatin;docetaxel;erlotinib hydrochloride
21 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
22 Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors Completed NCT00301756 Phase 2 Belinostat
23 MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer Recruiting NCT02068794 Phase 1, Phase 2
24 Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02923739 Phase 2 Paclitaxel
25 Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02122185 Phase 2 metformin hydrochloride;placebo;Chemotherapy
26 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT02101775 Phase 2 Adavosertib;Gemcitabine Hydrochloride
27 Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
28 First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Active, not recruiting NCT01097746 Phase 2 Carboplatin;Paclitaxel
29 Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer Active, not recruiting NCT00551070 Phase 2 Selumetinib Sulfate
30 Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Terminated NCT00331422 Phase 2 carboplatin;paclitaxel
31 TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Completed NCT01294293 Phase 1 TLR8 Agonist VTX-2337;Pegylated Liposomal Doxorubicin Hydrochloride;Paclitaxel
32 Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT01074411 Phase 1 Bortezomib;Carboplatin
33 Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer Completed NCT00060359 Phase 1 Carboplatin;Paclitaxel Poliglumex
34 Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00814086 Phase 1 Paclitaxel;Cisplatin
35 Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) Completed NCT00085358 Phase 1 carboplatin;paclitaxel;docetaxel
36 Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00079430 Phase 1 paclitaxel;carboplatin
37 Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer Completed NCT00002913 Phase 1 paclitaxel;cisplatin;topotecan hydrochloride
38 Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00006235 Phase 1 carboplatin;pegylated liposomal doxorubicin hydrochloride
39 Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission Completed NCT00002977 Phase 1 melphalan;thiotepa
40 Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00003967 Phase 1 etoposide;topotecan hydrochloride
41 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer Completed NCT00005026 Phase 1 carboplatin;paclitaxel;topotecan hydrochloride
42 Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors Completed NCT00066651 Phase 1
43 Immunotoxin Therapy in Treating Patients With Advanced Cancer Completed NCT00006981 Phase 1
44 Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00003385 Phase 1 carboplatin;paclitaxel;pegylated liposomal doxorubicin hydrochloride
45 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
46 Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT00989651 Phase 1 Carboplatin;Cisplatin;Paclitaxel;Veliparib
47 Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer Active, not recruiting NCT00408590 Phase 1
48 Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer Terminated NCT00003380 Phase 1 etoposide;pegylated liposomal doxorubicin hydrochloride
49 Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Completed NCT01080521
50 Collecting Tumor Samples From Patients With Gynecological Tumors Completed NCT00897442

Search NIH Clinical Center for Ovarian Brenner Tumor

Cochrane evidence based reviews: brenner tumor

Genetic Tests for Ovarian Brenner Tumor

Anatomical Context for Ovarian Brenner Tumor

MalaCards organs/tissues related to Ovarian Brenner Tumor:

41
Ovary, Testis, Kidney, Colon, Thymus, Small Intestine, Appendix

Publications for Ovarian Brenner Tumor

Articles related to Ovarian Brenner Tumor:

(show top 50) (show all 158)
# Title Authors Year
1
Undiagnosed tubal high-grade serous carcinoma metastatic to synchronous benign ovarian Brenner tumor. ( 29567918 )
2018
2
Ovarian Combined Brenner Tumor, Mucinous Cystadenoma and Struma Ovarii: First Report of a Rare Combination. ( 30134344 )
2018
3
Brenner tumor of the ovary - ultrasound features and clinical management of a rare ovarian tumor mimicking ovarian cancer. ( 30091444 )
2018
4
Mixed Ovarian Tumor Composed of Brenner Tumor and Adult-Type Granulosa Cell Tumor: A Case Report of a Very Rare Mixed Ovarian Tumor and a Review of the Literature. ( 29198156 )
2018
5
Malignant Brenner tumor: Two case reports. ( 30364765 )
2018
6
Coexisting Brenner Tumor and Endometrial Carcinoma. ( 28706410 )
2017
7
A peculiar case report of extraovarian Brenner tumor arising in the omentum. ( 28351362 )
2017
8
Vaginal Brenner tumor with literature review: does this tumour originate from Walthard nests? ( 28413211 )
2017
9
Malignant Brenner tumor associated with a germline BRCA2 mutation. ( 28616458 )
2017
10
Malignant Brenner tumor of the ovary: Review and case report. ( 28971141 )
2017
11
Brenner tumor of the testis: A case report and review of the literature. ( 28123743 )
2017
12
Testosterone Aromatization to Estradiol in Course of Ovarian Functioning Brenner Tumor Associated With Endometrial Carcinoma and Endometriosis (Roncati-Manenti Triad). ( 27465894 )
2016
13
Laparoscopic treatment of Castleman's disease in a patient with a history of malignant Brenner tumor. ( 27751433 )
2016
14
Malignant ovarian Brenner tumor. A case report evaluated with (18)F-FDG PET/CT. ( 25890890 )
2015
15
Different staining patterns of ovarian Brenner tumor and the associated mucinous tumor. ( 25596159 )
2015
16
Iliopsoas abscess due to brenner tumor malignancy: a case report. ( 25635448 )
2015
17
Intensive systemic chemotherapy is effective against recurrent malignant Brenner tumor of the ovary: An analysis of 10 cases within a single center. ( 25951724 )
2015
18
Disappearance of Upper Urinary Tract Urothelial Carcinoma after Treatment of a Borderline Brenner Tumor: Case Report and Literature Review. ( 26278583 )
2015
19
An unusual case of a borderline Brenner tumor associated with bilateral serous cystadenoma and endometrial carcinoma. ( 24791367 )
2014
20
Ovarian malignant Brenner tumor in patients over 65 years of age. ( 24581217 )
2014
21
Bilateral ovarian serous cystadenofibromas coexisting with an incidental unilateral Brenner tumor and Walthard cell rests in bilateral Fallopian tubes: an unusual case with diagnostic implications and histogenesis. ( 24943791 )
2014
22
Borderline Brenner tumor of the ovary: a case report with immunohistochemical and molecular study. ( 25358264 )
2014
23
Vaginal brenner tumor. ( 23370647 )
2013
24
Brenner tumor of the ovary revealed by cyst aspiration in a patient undergoing in vitro fertilization. ( 23477702 )
2013
25
FDG PET/CT of a benign ovarian Brenner tumor. ( 22920385 )
2012
26
Malignant Brenner tumor of the ovary: analysis of 13 cases. ( 21796330 )
2012
27
Malignant Brenner tumor of the ovary with transformation to trabecular carcinoid: an immunocytochemical and electron microscopic study. ( 22123728 )
2012
28
Diffusion-weighted imaging of a malignant brenner tumor. ( 22450390 )
2012
29
A borderline ovarian Brenner tumor mimicks uterine fibroids. ( 21482385 )
2011
30
Brenner tumor of ovary: An incidental finding. ( 21897739 )
2011
31
Unusual presentation of benign cystic brenner tumor with exuberant psammomatous calcifications. ( 21087980 )
2011
32
A singular observation of a giant benign Brenner tumor of the ovary. ( 21594602 )
2011
33
Proliferative Brenner tumor of the ovary. clinicopathological study of two cases and review of the literature. ( 22053680 )
2011
34
Dural metastases as a presentation of a Brenner tumor. ( 20110171 )
2010
35
Ascitic fluid cytology in malignant Brenner tumor: a case report. ( 20715663 )
2010
36
Unique cytomorphologic features of Brenner tumor of the ovary: a case report. ( 21053569 )
2010
37
Endometroid adenocarcinoma of the uterus, borderline tumor of the ovary and Brenner tumor of the contralateral ovary in a 63-year-old woman. ( 21061809 )
2010
38
Bilateral proliferating Brenner tumor of the ovary associated with recurrent urothelial carcinoma of the urinary bladder. ( 22624111 )
2010
39
Brenner tumor in pregnancy: clinical approach and pathological findings. ( 19527401 )
2009
40
Primary ovarian leiomyosarcoma associated with Brenner tumor. ( 19761141 )
2009
41
Color Doppler sonographic features of a Brenner tumor in pregnancy. ( 19778892 )
2009
42
Malignant Brenner tumor with transition from benign to malignant components: computed tomographic and magnetic resonance imaging findings with pathological correlation. ( 18664841 )
2008
43
Transitional cell carcinoma of the endometrium associated with benign ovarian brenner tumor: a case report with immunohistochemistry molecular analysis and a review of the literature. ( 17581415 )
2007
44
A case of virilizing brenner tumor in a postmenopausal woman with stromal androgenic activity. ( 16810058 )
2006
45
Left ovarian Brenner tumor. ( 16302335 )
2005
46
Metastatic Brenner tumor--a case report. ( 16334984 )
2005
47
Borderline Brenner tumor of the ovary: MRI findings. ( 15024513 )
2004
48
Brenner tumor of the ovary with striking microcystic change. ( 12649675 )
2003
49
Pathologic quiz case: urinary obstruction in a 78-year-old woman with a pelvic mass. Brenner tumor. ( 12951996 )
2003
50
Polypoid Brenner tumor of the uterus. ( 11781531 )
2002

Variations for Ovarian Brenner Tumor

Expression for Ovarian Brenner Tumor

Search GEO for disease gene expression data for Ovarian Brenner Tumor.

Pathways for Ovarian Brenner Tumor

Pathways related to Ovarian Brenner Tumor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.16 KRT13 KRT18 KRT20 KRT7
2
Show member pathways
11.91 KRT13 KRT18 KRT20 KRT7
3
Show member pathways
11.53 KRT13 KRT18 KRT7
4 11 KIT MME THBD
5 10.67 MME PAX2 WT1
6 10.46 PAX2 PAX8

GO Terms for Ovarian Brenner Tumor

Cellular components related to Ovarian Brenner Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 keratin filament GO:0045095 9.13 KRT13 KRT18 KRT7
2 intermediate filament GO:0005882 8.92 KRT13 KRT18 KRT20 KRT7

Biological processes related to Ovarian Brenner Tumor according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 keratinization GO:0031424 9.93 KRT13 KRT18 KRT20 KRT7
2 anatomical structure morphogenesis GO:0009653 9.85 GATA3 KRT18 PAX8
3 male gonad development GO:0008584 9.83 GATA3 KIT WT1
4 inner ear morphogenesis GO:0042472 9.81 GATA3 PAX2 PAX8
5 cornification GO:0070268 9.8 KRT13 KRT18 KRT20 KRT7
6 branching involved in ureteric bud morphogenesis GO:0001658 9.77 PAX2 PAX8 WT1
7 ventricular septum development GO:0003281 9.69 GATA3 PAX8 SALL4
8 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.67 PAX2 PAX8
9 cell fate determination GO:0001709 9.67 GATA3 PAX2
10 embryonic hemopoiesis GO:0035162 9.66 GATA3 KIT
11 urogenital system development GO:0001655 9.66 PAX2 PAX8
12 negative regulation of programmed cell death GO:0043069 9.65 KIT PAX2
13 cellular response to gonadotropin stimulus GO:0071371 9.65 PAX8 WT1
14 metanephric mesenchyme development GO:0072075 9.64 PAX2 WT1
15 mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0003337 9.63 PAX2 PAX8
16 otic vesicle development GO:0071599 9.62 GATA3 PAX8
17 pronephros development GO:0048793 9.62 PAX2 PAX8
18 regulation of metanephric nephron tubule epithelial cell differentiation GO:0072307 9.61 PAX2 PAX8
19 metanephric S-shaped body morphogenesis GO:0072284 9.61 PAX8 WT1
20 metanephric distal convoluted tubule development GO:0072221 9.59 PAX2 PAX8
21 metanephric nephron tubule formation GO:0072289 9.58 PAX2 PAX8
22 positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0072108 9.58 PAX2 PAX8
23 ureter maturation GO:0035799 9.57 GATA3 PAX2
24 mast cell differentiation GO:0060374 9.56 GATA3 KIT
25 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.55 PAX2 PAX8
26 nephric duct formation GO:0072179 9.54 GATA3 PAX2
27 positive regulation of thyroid hormone generation GO:2000611 9.52 GATA3 PAX8
28 tissue development GO:0009888 9.5 GATA3 SALL4 WT1
29 negative regulation of apoptotic process involved in metanephric collecting duct development GO:1900215 9.48 PAX2 PAX8
30 negative regulation of apoptotic process involved in metanephric nephron tubule development GO:1900218 9.46 PAX2 PAX8
31 negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis GO:0072305 9.43 PAX2 PAX8
32 mesonephros development GO:0001823 9.43 GATA3 PAX2 PAX8
33 positive regulation of metanephric DCT cell differentiation GO:2000594 9.4 PAX2 PAX8
34 pronephric field specification GO:0039003 9.37 PAX2 PAX8
35 kidney development GO:0001822 9.35 GATA3 MME PAX8 UPK3A WT1
36 mesenchymal to epithelial transition GO:0060231 9.33 GATA3 PAX2 WT1
37 metanephric epithelium development GO:0072207 8.8 PAX2 PAX8 WT1

Molecular functions related to Ovarian Brenner Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.55 ANO1 GATA3 KIT KRT13 KRT18 KRT20
2 transcription regulatory region DNA binding GO:0044212 9.26 GATA3 PAX2 PAX8 WT1

Sources for Ovarian Brenner Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....